Vollständige Liste der 229 Quellen der Gesamtstudie in der Reihenfolge der Kennungen (nach Jahr absteigend, dann nach Autor). Form: [sNN] Autoren (Jahr): Titel. Zeitschrift. PMID/DOI. Originaltitel bleiben im Original; bei Titeln in anderen Sprachen als Englisch und Deutsch steht die deutsche Übersetzung in Klammern. Bei Quellen ohne PMID und DOI steht, soweit vorhanden, die Adresse des Eintrags. Bei Zeitschriftenangaben mit Seitenzahlen stammen diese aus den Datenbankeinträgen.
[s01] Baboudjian M, Creta M, Pyrgidis N, Moris L, Duran MB, de Nunzio C, et al. (2026): Summary Paper on the 2026 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms. European urology. PMID 41997777; DOI 10.1016/j.eururo.2026.03.020
[s02] Bettencourt A, Wu J, Borrell JA, Furtado TP, Mills JN, Jayadevan R, et al. (2026): Ejaculatory function after robotic waterjet ablation for the treatment of benign prostatic hyperplasia: a systematic review. International journal of impotence research. PMID 40369187; DOI 10.1038/s41443-025-01087-6
[s03] Deng H, Zhang J (2026): Clinical outcomes of in vitro fertilization using testicular sperm versus urinary-recovered sperm in men with complete retrograde ejaculation: A single-center, retrospective, comparative study. Medicine (Baltimore):e49120. PMID 42216385; DOI 10.1097/md.0000000000049120
[s04] EAU Guidelines Panel on Non-neurogenic Male LUTS (2026): EAU Guidelines on the Management of Non-neurogenic Male LUTS (Webfassung, Kapitel Treatment). European Association of Urology (uroweb.org). ohne PMID/DOI (https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts/chapter/treatment)
[s05] Gezmiş CT, Çilesiz NC, Kartal VH, Altan MK, Çakıroğlu B, Balcı MBC (2026): Correlation between intravesical prostatic protrusion and ejaculatory dysfunction after tamsulosin treatment in men with BPH. World journal of urology. PMID 41703363; DOI 10.1007/s00345-026-06266-8
[s06] Giulioni C, Cafarelli A, Falsetti F, Spinozzi L, Piazza P, Orecchia L, et al. (2026): Ejaculation-sparing endoscopic surgery for benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials. World journal of urology. PMID 41964756; DOI 10.1007/s00345-026-06397-y
[s07] Gong Z, He J, Feng Q, Chen W, Xu Y, Wang Q, et al. (2026): Androgenetic alopecia drugs and male infertility: Evidence from pharmacovigilance and testicular transcriptomics. PloS one. PMID 42784576; DOI 10.1371/journal.pone.0357154
[s08] Gong Z, He J, Feng Q, Liu D, Liu S (2026): Drug-induced male infertility: a real-world study using FAERS and EudraVigilance databases. Frontiers in pharmacology. PMID 41693779; DOI 10.3389/fphar.2026.1765071
[s09] Goueli R, Badlani GH, Welliver C, Anderson PD, Bauer SR, Dana T, et al. (2026): Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part I: Presentation and Evaluation. The Journal of urology. PMID 42095481; DOI 10.1097/ju.0000000000005097
[s10] Goueli R, Badlani GH, Welliver C, Anderson PD, Bauer SR, Dana T, et al. (2026): Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part II: Medical Management. The Journal of urology. PMID 42095477; DOI 10.1097/ju.0000000000005098
[s11] Goueli R, Badlani GH, Welliver C, Anderson PD, Bauer SR, Dana T, et al. (2026): Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part III: Procedural/Surgical Management. The Journal of urology. PMID 42095468; DOI 10.1097/ju.0000000000005099
[s12] Iossa V, Imperatore V, Buonopane R, Di Girolamo A, Fiore F, Sessa G, et al. (2026): Temporary pharmacologically induced ejaculatory dysfunction influences surgical decision-making in sexually active men with benign prostatic hyperplasia: a prospective interventional study. International urology and nephrology. PMID 42782435; DOI 10.1007/s11255-026-05406-8
[s13] Lopes LS, Candelaria JD, Glina FPA, Feitosa TV, de Oliveira BBP, Baccaglini WRC, et al. (2026): Single-dose Tamsulosin Induces Reversible Azoospermia and Ejaculatory Dysfunction Suggesting Potential for on-demand Male Contraception. International braz j urol : official journal of the Brazilian Society of Urology. PMID 41770987; DOI 10.1590/s1677-5538.ibju.2025.0601
[s14] Mari A, Cindolo L, Fiori C, Lambertini L, Secco S, Russo GI, et al. (2026): Trends for ejaculatory sparing and minimally invasive surgical treatments adoption for lower urinary tract symptoms related to BPH in Italy: screenshot from the Italian society of urology (SIU) benign research network. Minerva urology and nephrology. PMID 41697212; DOI 10.23736/s2724-6051.25.06569-3
[s15] Nouh I, Eldib H, Noah K, Farag M (2026): Efficacy of daily silodosin 8 mg as a potential reversible male contraceptive: A prospective placebo controlled study. International urology and nephrology. PMID 41269482; DOI 10.1007/s11255-025-04885-5
[s16] Qian J, Gong Y, Zhang C, Zhou L (2026): Drug combination choices of 5α-reductase inhibitors and α-blockers in patients with benign prostatic hyperplasia: a study based on the FAERS database. Front Med (Lausanne):1870053. PMID 42375193; DOI 10.3389/fmed.2026.1870053
[s17] Roztocka A, Osiński P, Car H, Nazarko N, Czech EK, Sokołowska E (2026): Alpha-Adrenoceptor Blockade as a Novel Pathway Toward Non-Hormonal Male Contraception: A Mechanistic and Clinical Evidence Review. Journal of clinical medicine. PMID 42739649; DOI 10.3390/jcm15176643
[s18] Zitzmann M (2026): Male contraception-scientific foundations and contemporary progress (Männliche Kontrazeption: wissenschaftliche Grundlagen und aktuelle Fortschritte). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. PMID 41746363; DOI 10.1007/s00103-026-04208-8
[s19] Abdellatif A, Elbatanouny A, Ragheb A, Abdelbary A, Eid A, Lotfy AM, Mahmoud O, Youssef M, Abdallah M (2025): Comparative evaluation of safety and efficacy of dapoxetine, silodosin, and citalopram in the management of premature ejaculation: a randomized clinical trial. BMC urology. PMID 41327131; DOI 10.1186/s12894-025-01973-7
[s20] Abdullaev SP, Shatokhin MN, Bochkov PO, Tuchkova SN, Loran OB, Abdullaev SP, Mirzaev KB, Sychev DA (2025): Genetic Modulation of Silodosin Exposure and Efficacy: The Role of CYP3A4, CYP3A5, and UGT2B7 Polymorphisms in Benign Prostatic Hyperplasia Management. Journal of personalized medicine. PMID 40863448; DOI 10.3390/jpm15080386
[s21] Alshahrani S, Binsaleh A, Alghamdi AO, Alqasem S, Al-Gonaim A, El-Metwally A (2025): Perceptions and Practice of Urologists in Saudi Arabia Regarding Sexual Complications Related to LUTS/BPH Management. Journal of clinical medicine. PMID 40566111; DOI 10.3390/jcm14124367
[s22] Anract J, Klein C, Sarrazin C, Pinar U, Chevrot A, Fassi-Fehri H, et al. (2025): Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: Guidelines of the French LUTS Committee (CTMH). The French journal of urology. PMID 41271371; DOI 10.1016/j.fjurol.2025.102952
[s23] Guo Y, Sun F, Wang Y, Li Y, Wang T, Ma X, Wu J (2025): The efficacy and safety of mirabegron and α-adrenergic receptor antagonist in the treatment of distal ureteral stones: a systematic review and meta-analysis. Front Pharmacol:1517979. PMID 40176903; DOI 10.3389/fphar.2025.1517979
[s24] Kim YJ, Lee SR, Yu YD (2025): Long-term use of dutasteride to treat androgenic alopecia in young men may lead to persistent abnormalities in semen parameters. Clinical and experimental reproductive medicine. PMID 40114308; DOI 10.5653/cerm.2024.07675
[s25] Konstantinidis C, Zachariou A, Evgeni E, Çayan S, Boeri L, Agarwal A (2025): Recent Advances in the Diagnosis and Management of Retrograde Ejaculation: A Narrative Review. Diagnostics. PMID 40150068; DOI 10.3390/diagnostics15060726
[s26] Li J, Ai C, Yuan C, Wang K, Yu L, Jian Z, et al. (2025): Silodosin in treating men With BPH-associated lower urinary tract Symptoms: A systematic review and network meta-analysis. International journal of surgery (London, England). PMID 41346266; DOI 10.1097/js9.0000000000004023
[s27] Oh KT, Kim JH (2025): Aquablation versus HoLEP: Propensity score matching analysis of functional outcomes and ejaculation preservation. Investigative and clinical urology. PMID 40897661; DOI 10.4111/icu.20250055
[s28] Ramachandran A, Chavannavar KM, Velmurugan P, Sekar H, Krishnamoorthy S (2025): Surgery without Sacrifice: Understanding Ejaculation-Preserving TURP. Buchkapitel (Bookpi). DOI 10.9734/bpi/mono/978-93-49238-86-2/CH1
[s29] Singh D, Nguyen T, Burnam P, Greenberg J, Raheem O, Hellstrom W (2025): Benign Prostatic Hyperplasia and Sexual Dysfunction: Review of the Impact of New Medical and Surgical Therapies on Sexual Health. Current urology reports. PMID 40490610; DOI 10.1007/s11934-025-01279-z
[s30] Sonmez B, Uzun H, Huner Yigit M, Akca G, Dil E, Orman E, Kacan Y (2025): Silodosin-induced anejaculation: a promising agent for male oral contraception (Silodosin-induzierte Anejakulation: ein vielversprechender Wirkstoff für die orale männliche Verhütung). Revista Internacional de Andrología 23(2). ohne PMID/DOI (https://dialnet.unirioja.es/servlet/articulo?codigo=10290027)
[s31] Tan H, Luo L, Li W, Lan W, Chen Y, Huang G, Yang J, Xi X (2025): A pharmacovigilance study of drug-reduced male semen quality based on the Food and Drug Administration adverse event reporting system database. Andrology:217-225. PMID 38831673; DOI 10.1111/andr.13668
[s32] Wu L, Rao M, Chen Y, Wang H (2025): Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system. J Sex Med:2058-2069. PMID 40971937; DOI 10.1093/jsxmed/qdaf227
[s33] Zhang J, Wang D, Chi J, Lou K, Wu J, Cui Y (2025): A systematic review and meta-analysis of the efficacy and safety of mirabegron vs. tamsulosin in alleviating double-J catheter related symptoms. Front Med (Lausanne):1669827. PMID 41255616; DOI 10.3389/fmed.2025.1669827
[s34] Дианов М. П., Кызласов П. С., Соловьев А. В., Мустафаев А. Т (2025): ВЛИЯНИЕ ЭЯКУЛЯТОРНОЙ ДИСФУНКЦИИ НА ЭМОЦИОНАЛЬНО-ПСИХОЛОГИЧЕСКОЕ СОСТОЯНИЕ ПАЦИЕНТА ПРИ ЛЕЧЕНИИ ДОБРОКАЧЕСТВЕННОЙ ГИПЕРПЛАЗИИ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ (Einfluss der Ejakulationsstörung auf den emotional-psychischen Zustand bei der BPH-Behandlung). Бюллетень медицинской науки 2025(1). DOI 10.31684/25418475-2025-1-60
[s35] Brannigan RE, Hermanson L, Kaczmarek J, Kim SK, Kirkby E, Tanrikut C (2024): Updates to Male Infertility: AUA/ASRM Guideline (2024). The Journal of urology. PMID 39145501; DOI 10.1097/ju.0000000000004180
[s36] Fauzan MI, Daryanto B, Budaya TN, Makkaraka MAG, Fakhri M, Rahman IA (2024): Promising selective alpha-1 blocker silodosin as a new therapeutic strategy for premature ejaculation and analysis of its drug adverse effect: A systematic review and meta-analysis of randomized controlled trials. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica. PMID 39692416; DOI 10.4081/aiua.2024.12984
[s37] Gemma L, Pecoraro A, Sebastianelli A, Spatafora P, Sessa F, Nicoletti R, et al. (2024): Impact of minimally invasive surgical procedures for Male Lower Urinary Tract Symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review. Prostate cancer and prostatic diseases. PMID 38355729; DOI 10.1038/s41391-024-00795-2
[s38] Halawani A, Paterson R, Zhong T, Du K, Ren R, Forbes CM (2024): Risks and side effects in the medical management of benign prostatic hyperplasia. Prostate international. PMID 39036761; DOI 10.1016/j.prnil.2023.11.004
[s39] Kaltsas A, Kratiras Z, Zachariou A, Dimitriadis F, Sofikitis N, Chrisofos M (2024): Evaluating the Impact of Benign Prostatic Hyperplasia Surgical Treatments on Sexual Health. Biomedicines. PMID 38255215; DOI 10.3390/biomedicines12010110
[s40] Lee HY, Pyun JH, Shim SR, Kim JH (2024): Efficacy of Various Treatment in Premature Ejaculation: Systematic Review and Network Meta-Analysis. The world journal of men's health. PMID 37635338; DOI 10.5534/wjmh.230030
[s41] Lee H, Lee JH, Choo MS, Cho MC, Son H, Jeong H, Yoo S (2024): Factors Considered by Experienced Urologists when Selecting Alpha-Blockers for Patients with Lower Urinary Tract Symptoms or Benign Prostatic Hyperplasia according to Age. Urol Int:434-441. PMID 38749410; DOI 10.1159/000539313
[s42] Machado NR, Miyazaki MA, Oliveira TD, Dias KT, Colli LG, Belardin LB, et al. (2024): Systemic alpha-1 adrenergic receptor inhibition reduces sperm damage in adult and aging spontaneously hypertensive rats. Scientific reports. PMID 39567544; DOI 10.1038/s41598-024-77661-7
[s43] Nacchia A, Franco A, Cicione A, Riolo S, Santoro G, Romagnoli M, et al. (2024): Medications Mostly Associated With Ejaculatory Disorders: Assessment of the Eudra-Vigilance and Food and Drug Administration Pharmacovigilance Databases Entries. Urology. PMID 38331221; DOI 10.1016/j.urology.2023.12.021
[s44] Tawfik A, Abo-Elenen M, Gaber M, El-Abd A, Zoeir A, Saad S, Sultan I, Ghoneim A (2024): Tadalafil versus tamsulosin as combination therapy with 5-alpha reductase inhibitors in benign prostatic hyperplasia, urinary and sexual outcomes. World journal of urology. PMID 38308714; DOI 10.1007/s00345-023-04735-y
[s45] Yan H, Li X, Zheng X, Cui Y, Huang J, Cheng Y (2024): Evaluating the safety and effectiveness of α-blockers versus mirabegron for medical expulsive therapy in ureteral calculi: A Systematic review and meta-analysis. PLoS One:e0315328. PMID 39729463; DOI 10.1371/journal.pone.0315328
[s46] Yoosuf BT, Panda AK, Kt MF, Bharti SK, Devana SK, Bansal D (2024): Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis. Scientific reports. PMID 38750153; DOI 10.1038/s41598-024-61977-5
[s47] Yoshizumi M, Ise SN, Yonezawa A, Watanabe C, Sakurada S, Mizoguchi H (2024): Characteristics of α1-adrenoceptor antagonists-induced ejaculatory dysfunction on spontaneous seminal emission in rats. Basic & clinical pharmacology & toxicology. PMID 38409579; DOI 10.1111/bcpt.13993
[s48] Abdullaev Sh P, Shatokhin M N, Tuchkova S N, Abdullaev Sh P, Teodorovich O V, Loran O B, Sychev D A (2023): Study of allelic variants of the CYP2D6 and CYP3A genes on the effectiveness and safety of tamsulosin therapy in patients with BPH: results of a pilot study (Untersuchung allelischer Varianten der Gene CYP2D6 und CYP3A hinsichtlich Wirksamkeit und Sicherheit der Tamsulosin-Therapie bei Patienten mit benigner Prostatahyperplasie: Ergebnisse einer Pilotstudie). Urologiia. PMID 38156677
[s49] Yiğit Akın, Osman Köse, Sacit Nuri Görgel, Serkan Özcan, Enis Mert Yorulmaz, Kürşad Dönmez (2023): Alfa blokerlerin ejakülasyon üzerine etkisi: Literatür güncellemesi (Wirkung von Alpha-Blockern auf die Ejakulation: Literaturaktualisierung). Androloji Bülteni 2023:208-211. DOI 10.24898/tandro.2023.91489
[s50] Bschleipfer T, Abt SD, Becher KF, Dreikorn K, Höfner K, Madersbacher S, et al. (2023): Conservative and pharmacological treatment of benign prostatic hyperplasia : The German S2e-guideline 2023-part2 (Konservative und medikamentöse Behandlung der benignen Prostatahyperplasie: die deutsche S2e-Leitlinie 2023, Teil 2). Urologie (Heidelberg, Germany). PMID 37796278; DOI 10.1007/s00120-023-02183-5
[s51] de la Taille A, Chalret du Rieu Q, Dialla O, Bardin L (2023): Alpha-blockers or hexanic extract of Serenoa repens for 6 months: sub-analysis of the PERSAT study (Alphablocker oder hexanischer Extrakt von Serenoa repens über 6 Monate: Subanalyse der PERSAT-Studie). Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. PMID 36207246; DOI 10.1016/j.purol.2022.09.018
[s52] Gravas S, Gacci M, Gratzke C, Herrmann TRW, Karavitakis M, Kyriazis I, et al. (2023): Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms. European urology. PMID 37202311; DOI 10.1016/j.eururo.2023.04.008
[s53] Magistro G, Abt SD, Becher KF, Bschleipfer T, Dreikorn K, Höfner K, et al. (2023): Surgical treatment options of lower urinary tract symptoms due to benign prostatic obstruction : The German S2e guideline 2023-part 3 (Operative Behandlungsoptionen bei Beschwerden der unteren Harnwege durch benigne Prostataobstruktion: die deutsche S2e-Leitlinie 2023, Teil 3). Urologie (Heidelberg, Germany). PMID 37823934; DOI 10.1007/s00120-023-02200-7
[s54] Rustamov MN, Galiullin OF, Vinarov AZ (2023): Ejaculatory disorders after surgical treatment of benign prostatic hyperplasia (Ejakulationsstörungen nach chirurgischer Behandlung der benignen Prostatahyperplasie). Urologiia. PMID 37401683; DOI 10.18565/urology.2023.1.46-52
[s55] Soliman MG, Al-Ghadeer MR, Al-Shabaan HR, Al-Hamrani AH, AlGhadeer HA (2023): Evaluation of intermittent tamsulosin in treating symptomatic patients with benign prostatic hyperplasia. Urology annals. PMID 37006221; DOI 10.4103/ua.ua_143_21
[s56] Taniguchi H, Inoue T, Kawa G, Murota T, Tsukino H, Yoshimura K, Kamoto T, Ogawa O, Matsuda T, Kinoshita H (2023): Evaluation of sexual function after dutasteride treatment in patients with once-negative prostate biopsy and benign prostate hyperplasia. Urologia:295-300. PMID 36992564; DOI 10.1177/03915603231163201
[s57] Akhavizadegan H, Sadighi Gilani MA, Amirjannati N, Heidari M (2022): Sperm Retrieval in Non-azoospermic Patients with Persistent Ejaculation Dysfunction. Journal of reproduction & infertility. PMID 36415494; DOI 10.18502/jri.v23i3.10004
[s58] Britto-Júnior J, Ribeiro A, Ximenes L, Lima AT, Jacintho FF, Fregonesi A, et al. (2022): Alpha1-adrenergic antagonists block 6-nitrodopamine contractions on the rat isolated epididymal vas deferens. European journal of pharmacology. PMID 34951979; DOI 10.1016/j.ejphar.2021.174716
[s59] Flores RB, Angrimani DSR, Brito MM, de Almeida LL, Lopes JVM, Losano JDA, et al. (2022): Frozen-Thawed Sperm Analysis of Benign Prostatic Hyperplasia Dogs Treated With Finasteride. Frontiers in veterinary science. PMID 35847633; DOI 10.3389/fvets.2022.901943
[s60] Manfredi C, García-Gómez B, Arcaniolo D, García-Rojo E, Crocerossa F, Autorino R, et al. (2022): Impact of Surgery for Benign Prostatic Hyperplasia on Sexual Function: A Systematic Review and Meta-analysis of Erectile Function and Ejaculatory Function. European urology focus. PMID 35803852; DOI 10.1016/j.euf.2022.06.007
[s61] Mansbart F, Kienberger G, Sönnichsen A, Mann E (2022): Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing. BMC geriatrics. PMID 36171560; DOI 10.1186/s12877-022-03415-7
[s62] Novikov AI, Shpilenya ES (2022): Therapeutic efficacy and safety of monotherapy Alfuprost MR 10 mg/day in clinical practice (Therapeutische Wirksamkeit und Sicherheit der Monotherapie mit Alfuprost MR in der klinischen Praxis). Urologiia. PMID 35485809
[s63] Pushkar DY, Loran OB, Bernikov AN (2022): The influence of alfuzosin monotherapy on the sexual function of patients with benign prostatic hyperplasia in real clinical practice (results of a Russian multicenter study) (Einfluss der Alfuzosin-Monotherapie auf die Sexualfunktion von Patienten mit benigner Prostatahyperplasie in der klinischen Praxis (Ergebnisse einer russischen multizentrischen Studie)). Urologiia. PMID 36625609; DOI 10.18565/urology.2022.6.21-29
[s64] Seidensticker M, Tasch S, Mietens A, Exintaris B, Middendorff R (2022): Treatment of benign prostatic hyperplasia and abnormal ejaculation: live imaging reveals tamsulosin - but not tadalafil - induced dysfunction of prostate, seminal vesicles and epididymis. Reproduction. PMID 36173812; DOI 10.1530/rep-22-0197
[s65] Zhang JJ, Shi X, Wu T, Zhang MD, Tang J, Yin GM, Long Z, He LY, Qi L, Wang L (2022): Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis. Asian J Androl:390-397. PMID 34747724; DOI 10.4103/aja202171
[s66] Akgül M, Yazıcı C, Şipal T, Arda E (2021): The clinical significance of abnormal ejaculation by silodosin. Is it important?. Andrologia. PMID 33951747; DOI 10.1111/and.14086
[s67] Couteau N, Duquesne I, Frédéric P, Thiounn N, Timsit MO, Mejean A, et al. (2021): Ejaculations and Benign Prostatic Hyperplasia: An Impossible Compromise? A Comprehensive Review. Journal of clinical medicine. PMID 34945084; DOI 10.3390/jcm10245788
[s68] Guo J, Tang R (2021): Efficacy and tolerability of doxazosin gastro-intestinal therapeutic system versus tamsulosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A systematic review and meta-analysis. Medicine (Baltimore):e26955. PMID 34414962; DOI 10.1097/md.0000000000026955
[s69] Gupta SP, Sharma RK, Agarwal A, et al. (2021): A comprehensive guide to sperm recovery in infertile men with retrograde ejaculation. The World Journal of Men's Health. DOI 10.5534/WJMH.210069
[s70] Yu ZW, Wang RH, Zhang CC, Gao JG (2021): The efficacy and safety of alpha-adrenergic blockers for medical expulsion therapy in patients with ureteral calculi: A meta-analysis of placebo-controlled trials. Medicine (Baltimore):e27272. PMID 34664882; DOI 10.1097/md.0000000000027272
[s71] ‘Andrology Study Group of Society of Urologic Surgery-Turkey (SUST)’, Cihan A, Kazaz İO, Yıldırım Ö, Deliktaş H, Ongün Ş, Gül Ü, Şahin B, Üre İ, Özkara H (2020): Changing Aspects of Male Sexual Functions Accompanying Treatment of Benign Prostatic Hyperplasia With Silodosin 8 mg Per Day. The journal of sexual medicine. PMID 32217036; DOI 10.1016/j.jsxm.2020.02.023
[s72] Angrimani DSR, Bicudo LC, Llamas Luceño N, Rui BR, Silva MF, Losano JDA, et al. (2020): Does finasteride treatment for benign prostatic hyperplasia influence sperm DNA integrity in dogs?. Basic and clinical andrology. PMID 32695403; DOI 10.1186/s12610-020-00108-2
[s73] Bhat GS, Shastry A (2020): A prospective double-blind, randomized, placebo-controlled study to evaluate the efficacy of silodosin 8 mg as an on-demand, reversible, nonhormonal oral contraceptive for males: a pilot study. World journal of urology. PMID 31076850; DOI 10.1007/s00345-019-02806-7
[s74] de la Taille A, Bardin L, Castagné C, Auges M, Capronnier O, Chalret du Rieu Q (2020): Alpha-blockers or phytotherapy as first-line treatment of LUTS/BPH in general medicine: The PERSAT non-interventional study (Alphablocker oder Phytotherapie als Erstbehandlung von LUTS/BPH in der Allgemeinmedizin: die nicht-interventionelle Studie PERSAT). Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. PMID 32753297; DOI 10.1016/j.purol.2020.07.001
[s75] Egui Rojo MA, Redón Gálvez L, Álvarez Ardura M, Otaola Arca H, Páez Borda A (2020): Comparison of monopolar versus bipolar transurethral resection of the prostate: Evaluation of the impact on sexual function (Vergleich der monopolaren und bipolaren transurethralen Resektion der Prostata: Bewertung der Auswirkungen auf die Sexualfunktion). Revista internacional de andrologia. PMID 30612924; DOI 10.1016/j.androl.2018.07.008
[s76] Gul A, Coban S, Turkoglu AR, Guzelsoy M, Ozturk M, Kankilic NA (2020): Comparative efficacy and safety profile of 4 vs 8 mg of silodosin once daily usage in patients with benign prostatic hyperplasia-related lower urinary tract symptoms divided into subgroups according to International Prostate Symptom Score severity. Prostate international. PMID 33425792; DOI 10.1016/j.prnil.2020.04.002
[s77] Kohestani Y, Kohestani B, Shirmohamadi Z, Faghani M (2020): Effect of tamsulosin on testis histopathology and serum hormones in adult rats: Experimental study. International journal of reproductive biomedicine. PMID 32803117; DOI 10.18502/ijrm.v13i7.7370
[s78] Lokeshwar SD, Valancy D, Lima TFN, Blachman-Braun R, Ramasamy R (2020): A Systematic Review of Reported Ejaculatory Dysfunction in Clinical Trials Evaluating Minimally Invasive Treatment Modalities for BPH. Current urology reports. PMID 33104947; DOI 10.1007/s11934-020-01012-y
[s79] Renoncourt T (2020): Mésusage des traitements de l'hypertrophie bénigne de la prostate chez le sujet âgé (Fehlgebrauch der Behandlungen der benignen Prostatahyperplasie bei älteren Personen). Abschlussarbeit (Medizin), DUMAS/HAL. ohne PMID/DOI (https://dumas.ccsd.cnrs.fr/dumas-03164600v1)
[s80] Shiryaev AA, Govorov AV, Vasilyev AO, Pushkar DY (2020): Alpha1-adrenergic blockers therapy and sexual function (Therapie mit Alpha-1-Adrenoblockern und Sexualfunktion). Urologiia. PMID 33185353; DOI 10.18565/urology.2020.5.82-86
[s81] Xu XF, Liu GX, Zhu C, Qiao XM, Yu SF, Deng T, Jin YH (2020): α1-Blockers and 5α-Reductase Inhibitors Are the Most Recommended Drugs in Treating Benign Prostatic Hyperplasia: An Evidence-Based Evaluation of Clinical Practice Guidelines. Front Pharmacol:311. PMID 32269526; DOI 10.3389/fphar.2020.00311
[s82] Yu ZJ, Yan HL, Xu FH, Chao HC, Deng LH, Xu XD, Huang JB, Zeng T (2020): Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. Front Pharmacol:658. PMID 32457631; DOI 10.3389/fphar.2020.00658
[s83] Lebdai S, Chevrot A, Doizi S, Pradere B, Delongchamps NB, Benchikh A, et al. (2019): Do patients have to choose between ejaculation and miction? A systematic review about ejaculation preservation technics for benign prostatic obstruction surgical treatment. World journal of urology. PMID 29967947; DOI 10.1007/s00345-018-2368-6
[s84] Lee S, Lee YB, Choe SJ, Lee WS (2019): Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. Acta Derm Venereol:12-17. PMID 30206635; DOI 10.2340/00015555-3035
[s85] Otani T (2019): Clinical review of ejaculatory dysfunction. Reproductive medicine and biology. PMID 31607793; DOI 10.1002/rmb2.12289
[s86] Sertkaya Z, Ozkaya F (2019): Silodosin Has Nocebo Effect on Sexual Adverse Effects: A Randomized Controlled Trial. The Eurasian journal of medicine. PMID 31692743; DOI 10.5152/eurasianjmed.2019.19139
[s87] Shin YS, Karna KK, Choi BR, Park JK (2019): Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia. World J Mens Health:157-165. PMID 30209896; DOI 10.5534/wjmh.180029
[s88] Soliman MG, Abou-Ramadan AR, El-Abd AS, El-Tatawy HH, El-Abd SA, El-Sakka AA (2019): Outcome of Modification of Dose and Time of Administration of Tamsulosin in Men with Abnormal Ejaculation. Urologia internationalis. PMID 30840961; DOI 10.1159/000497295
[s89] Verze P, Califano G, Sokolakis I, Russo GI, Hatzichristodoulou G, Musi G, et al. (2019): The impact of surgery for lower urinary tract symptoms/benign prostatic enlargement on both erectile and ejaculatory function: a systematic review. International journal of impotence research. PMID 30996268; DOI 10.1038/s41443-019-0140-0
[s90] Yoshinaga R, Fukui T, Yoshifuji M, Fujimura M, Oyama T, Oka M (2019): Comparison of the Effects of Tadalafil and α1-Adrenoceptor Antagonists on Spontaneous Seminal Emission and Electrical Field Stimulation-Induced Seminal Vesicle Contraction in Rats. The journal of sexual medicine. PMID 30926520; DOI 10.1016/j.jsxm.2019.02.017
[s91] Zhao L, Tian R, Liang C, Zhang L, Song W, Zhao J, Wang Z, Ji Z, Xia S, Li Z (2019): Beneficial effect of tamsulosin combined with dapoxetine in management of type III prostatitis with premature ejaculation. Andrologia:e13319. PMID 31131928; DOI 10.1111/and.13319
[s92] Zhou Z, Cui Y, Wu J, Ding R, Cai T, Gao Z (2019): Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. BMC Urol:17. PMID 30871552; DOI 10.1186/s12894-019-0446-8
[s93] Hsu YP, Hsu CW, Bai CH, Cheng SW, Chen KC, Chen C (2018): Silodosin versus tamsulosin for medical expulsive treatment of ureteral stones: A systematic review and meta-analysis. PLoS One:e0203035. PMID 30153301; DOI 10.1371/journal.pone.0203035
[s94] Hwang EC, Gandhi S, Jung JH, Imamura M, Kim MH, Pang R, et al. (2018): Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. The Cochrane database of systematic reviews. PMID 30306544; DOI 10.1002/14651858.cd007360.pub3
[s95] Hwang EC, Gandhi S, Jung JH (2018): New alpha blockers to treat male lower urinary tract symptoms. Curr Opin Urol:273-276. PMID 29613909; DOI 10.1097/mou.0000000000000488
[s96] Rayburn ER, Gao L, Ding J, Ding H, Shao J, Li H (2018): FDA-approved drugs that are spermatotoxic in animals and the utility of animal testing for human risk prediction. Journal of assisted reproduction and genetics. PMID 29063992; DOI 10.1007/s10815-017-1062-8
[s97] Sun S, Wang YC, Guo K, DU J, Zhou HJ, Ren AJ (2018): Finasteride inhibits microvascular density and VEGF expression in the seminal vesicle of rats (Finasterid hemmt die Mikrogefäßdichte und die VEGF-Expression in der Samenblase von Ratten). Zhonghua Nan Ke Xue:387-392. PMID 30171751
[s98] Tsai TF, Choi GS, Kim BJ, Kim MB, Ng CF, Kochhar P, Jasper S, Brotherton B, Orban B, Lulic Z (2018): Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia. J Dermatol:799-804. PMID 29667763; DOI 10.1111/1346-8138.14329
[s99] Wang XP (2018): Therapeutic effects of α-adrenergic receptor antagonists on benign prostatic hyperplasia: A network meta-analysis (Therapeutische Wirkungen von Alpha-Adrenozeptor-Antagonisten bei benigner Prostatahyperplasie: eine Netzwerk-Metaanalyse). Zhonghua Nan Ke Xue:247-253. PMID 30161312
[s100] Cakiroglu B, Hazar AI, Sinanoglu O, Arda E, Ekici S (2017): Comparison of transurethral incision of the prostate and silodosin in patients having benign prostatic obstruction in terms of retrograde ejaculation. Archivio Italiano di Urologia e Andrologia. PMID 28403592; DOI 10.4081/aiua.2017.1.31
[s101] Choi WS, Cho MC, Lee JW, Song SH, Oh JK, Lee SW, Cho SY, Park JY (2017): Efficacy and safety of silodosin in the treatment of lower urinary tract symptoms in elderly men taking antihypertensive medications. Prostate Int:113-118. PMID 28828355; DOI 10.1016/j.prnil.2017.02.001
[s102] Homma Y, Gotoh M, Kawauchi A, Kojima Y, Masumori N, Nagai A, Saitoh T, Sakai H, Takahashi S, Ukimura O, Yamanishi T, Yokoyama O, Yoshida M, Maeda K (2017): Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Int J Urol:716-729. PMID 28748576; DOI 10.1111/iju.13401
[s103] Jung JH, Kim J, MacDonald R, Reddy B, Kim MH, Dahm P (2017): Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. The Cochrane database of systematic reviews. PMID 29161773; DOI 10.1002/14651858.cd012615.pub2
[s104] Kim SJ, Shin IS, Eun SJ, Whangbo TK, Kim JW, Cho YS, Kim JC (2017): Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients. Int Neurourol J:29-37. PMID 28361519; DOI 10.5213/inj.1734826.413
[s105] Sato Y, Otani T, Amano T, Araki T, Kondou N, Matsukawa M, et al. (2017): Silodosin versus naftopidil in the treatment of premature ejaculation: A prospective multicenter trial. International journal of urology : official journal of the Japanese Urological Association. PMID 28627033; DOI 10.1111/iju.13392
[s106] Wang T, Wang L, Liang Y, Ju J, Cai Y, Zhang J, Zhen H, Liu Y, Tang X, Wang J, Liu J (2017): Effect of α-receptor blockers on lower urinary tract symptoms, sexual function and quality of life in young and middle-aged men with benign prostatic hyperplasia. Exp Ther Med:587-592. PMID 28672971; DOI 10.3892/etm.2017.4518
[s107] Yuruk E, Pastuszak AW, Suggs JM, Colakerol A, Serefoglu EC (2017): The association between seminal vesicle size and duration of abstinence from ejaculation. Andrologia. PMID 27660049; DOI 10.1111/and.12707
[s108] Zeng XT, Li S, Gong K, Guo ZZ, Liu TZ, He DL, Wang XH (2017): Evidence-based evaluation of recent clinical practice guidelines for the diagnosis and treatment of benign prostatic hyperplasia (Evidenzbasierte Bewertung aktueller klinischer Leitlinien zur Diagnose und Behandlung der benignen Prostatahyperplasie). Zhonghua Yi Xue Za Zhi:1683-1687. PMID 28606274; DOI 10.3760/cma.j.issn.0376-2491.2017.22.002
[s109] Корнеев И. А., Зассеев Р. Д (2017): Преодоление бесплодия у мужчин с ретроградной эякуляцией и анэякуляцией (Überwindung der Infertilität bei Männern mit retrograder Ejakulation und Anejakulation). Урологические ведомости 7(2):10-15. DOI 10.17816/uroved7210-15
[s110] Hayashi T, Takeya M, Nakamura K, Matsuoka K (2016): Effects of Silodosin and Tamsulosin on the Seminal Vesicle Contractile Response. Low Urin Tract Symptoms:55-61. PMID 26789544; DOI 10.1111/luts.12072
[s111] Huang W, Xue P, Zong H, Zhang Y (2016): Efficacy and safety of silodosin in the medical expulsion therapy for distal ureteral calculi: a systematic review and meta-analysis. Br J Clin Pharmacol:13-22. PMID 26255996; DOI 10.1111/bcp.12737
[s112] (Kongressabstract, Autoren im Abstract nicht genannt) (2016): AB212. Clinical study on the treatment of lifelong premature ejaculation with Paroxetine hydrochloride and tamsulosin. Transl Androl Urol (Kongressabstracts). ohne PMID/DOI (https://europepmc.org/article/PMC/PMC4842688)
[s113] Liu L, Zhao S, Li F, Li E, Kang R, Luo L, Luo J, Wan S, Zhao Z (2016): Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials. J Sex Med:1297-1310. PMID 27475241; DOI 10.1016/j.jsxm.2016.07.006